

# **The Immunological Basis for Immunization Series**

Module 9: *Haemophilus influenzae* type b

**Immunization, Vaccines and Biologicals**



World Health  
Organization

# **The Immunological Basis for Immunization Series**

Module 9: *Haemophilus influenzae* type b

**Immunization, Vaccines and Biologicals**



World Health  
Organization

WHO Library Cataloguing-in-Publication Data

Haemophilus influenzae type b vaccines.

(Immunological basis for immunization series ; module 9)

1.Influenza, human - prevention and control. 2.Influenza vaccines - therapeutic use. 3.Influenza B virus - drug effect.  
I.World Health Organization. II.Series.

ISBN 978 92 4 159613 8

(NLM classification: WC 515)

**© World Health Organization 2007**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

---

**The Department of Immunization, Vaccines and Biologicals  
thanks the donors whose unspecified financial support  
has made the production of this document possible.**

This module was produced for Immunization, Vaccines and Biologicals, WHO, by:

- Professor David Goldblatt and Dr Tracy Assari, UCL Institute of Child Health, London, UK

*Printed in October 2007*

**Copies of this publications as well as additional materials  
on immunization, vaccines and biological may be requested from:**

World Health Organization  
Department of Immunization, Vaccines and Biologicals  
CH-1211 Geneva 27, Switzerland

- *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

**Printed by the WHO Document Production Services, Geneva, Switzerland**

---

# Contents

|   |            |
|---|------------|
| <i>Abbreviations and acronyms</i> .....   | <i>v</i>   |
| <i>Preface</i> .....  | <i>vii</i> |
| <b>1. The organism and the disease</b> .....  | <b>1</b>   |
| 1.1 Introduction .....  | 1          |
| 1.2 Epidemiology .....  | 1          |
| 1.3 The surface of Hib .....  | 4          |
| <b>2. The Immunology of Hib</b> .....   | <b>5</b>   |
| 2.1 Response to infection .....   | 6          |
| <b>3. Hib vaccines</b> .....  | <b>7</b>   |
| 3.1 Polysaccharide vaccine responses .....  | 7          |
| 3.2 Conjugate vaccine responses .....   | 8          |
| <b>4. Response to vaccination</b> .....   | <b>9</b>   |
| 4.1 Polysaccharide vaccine responses .....  | 9          |
| 4.2 Conjugate vaccine responses .....   | 9          |
| 4.3 Impact on Hib carriage .....  | 12         |
| 4.4 Impact of host factors .....  | 13         |
| 4.5 Hib conjugate vaccine efficacy .....  | 13         |
| <b>5. Vaccine formulation issues: Hib interchangeability and administration in combination</b> .....        | <b>15</b>  |
| 5.1 Interchanging different Hib conjugate vaccines .....  | 15         |
| 5.2 Simultaneous administration of Hib conjugate vaccines with other childhood vaccines .....               | 16         |
| 5.3 Hib combination vaccines .....  | 16         |
| <b>6. Vaccine schedule issues</b> .....   | <b>17</b>  |
| 6.1 Hib conjugate immunogenicity at 2/4/6 months (USA schedule) and effect of booster at 12-14 months ..... | 18         |
| 6.2 Hib conjugate immunogenicity at 2/3/4 months and effect of booster at 12-14 months .....                | 18         |
| 6.3 Hib conjugate immunogenicity at 3/5/12 months (Scandinavian schedule) .....                             | 19         |
| 6.4 Hib conjugate immunogenicity at 6/10/14 weeks (EPI schedule) .....                                      | 19         |

---

|           |  |           |
|-----------|--|-----------|
| <b>7.</b> | <b>Vaccine effectiveness .....</b>           | <b>21</b> |
| 7.1       | Developed country experience .....           | 22        |
| 7.2       | Developing country experience .....          | 25        |
| <b>8.</b> | <b>Future prospects .....</b>                | <b>27</b> |
| 8.1       | Hib conjugates in the EPI schedule .....     | 27        |
| 8.2       | Hib conjugates in combination vaccines ..... | 27        |
| 8.3       | The role of a booster dose .....             | 28        |
|           | <b>References .....</b>                      | <b>29</b> |

---

# Abbreviations and acronyms

|            |   |
|------------|---|
| aP         | acellular pertussis   |
| BCG        | bacille Calmette-Guérin (vaccine)                                       |
| BPIG       | bacterial polysaccharide immune globulin                                |
| CDC        | Centers for Disease Control & Prevention (USA)                          |
| CDSC       | Communicable Disease Surveillance Centre                                |
| CVI        | Children's Vaccine Initiative   |
| DTaP       | diphtheria-tetanus acellular pertussis                                  |
| DTP        | diphtheria-tetanus-pertussis (vaccine);                                 |
| DTwP       | diphtheria-tetanus whole-cell pertussis                                 |
| ELISA      | enzyme-linked immunosorbent assay                                       |
| EPI        | Expanded Programme on Immunization                                      |
| GAVI       | Global Alliance for Vaccines and Immunization                           |
| HepB       | Hepatitis B   |
| Hi         | Haemophilus influenzae  |
| Hib        | Haemophilus influenzae type b   |
| HIV        | human immunodeficiency virus  |
| HRU        | Health Research Unit  |
| Ig         | immunoglobulin  |
| IPV        | inactivated polio vaccine   |
| MMR        | measles, mumps, and rubella (vaccine)                                   |
| OMP        | outer membrane protein of polyribosyl-ribitol- phosphate                |
| OPV        | oral polio vaccine  |
| PHLS       | Public Health Laboratory Service  |
| PRP        | polyribosyl-ribitol -phosphate (carbohydrate of the Hib capsule)        |
| PRP-CRM197 | polyribosyl-ribitol- phosphate-CRM197 conjugate vaccine                 |
| PRP-OMP    | polyribosyl-ribitol- phosphate-outer membrane protein conjugate vaccine |
| PRP-T      | polyribosyl-ribitol- phosphate-tetanus toxoid conjugate vaccine         |
| PS         | polysaccharide  |

---

|        |   |
|--------|---|
| RIA    | radioimmunoassay                        |
| UCLA   | University of California at Los Angeles |
| UNICEF | The United Nations Children's Fund      |
| USA    | The United States of America            |
| WHO    | The World Health Organization           |
| wP     | whole-cell pertussis                    |

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29581](https://www.yunbaogao.cn/report/index/report?reportId=5_29581)

